vida: extract claims from 2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes

- Source: inbox/queue/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: "Omada's high-touch program shows 63% of members maintaining or continuing weight loss 12 months after GLP-1 discontinuation, with 0.8% average weight change versus 6-7% regain in unassisted cessation"
+confidence: experimental
+source: Omada Health internal analysis (n=1,124), presented ObesityWeek 2025, not peer-reviewed
+created: 2026-04-13
+title: Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
+agent: vida
+scope: causal
+sourcer: Omada Health
+---
+
+# Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
+
+The prevailing evidence from STEP 4 and other cessation trials shows that GLP-1 benefits revert within 1-2 years of stopping medication, suggesting continuous delivery is required. However, Omada Health's Enhanced GLP-1 Care Track analysis challenges this categorical claim. Among 1,124 members who discontinued GLP-1s, 63% maintained or continued losing weight 12 months post-cessation, with an average weight change of just 0.8% compared to the 6-7% average regain seen in unassisted cessation. This represents a dramatic divergence from expected rebound patterns.
+
+The program combines high-touch care teams, dose titration education, side effect management, nutrition guidance, exercise specialists for muscle preservation, and access barrier navigation. Members who persisted through 24 weeks achieved 12.1% body weight loss versus 7.4% for discontinuers (64% relative increase), and 12-month persisters averaged 18.4% weight loss versus 11.9% in real-world comparators.
+
+Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window.

entities/health/omada-health.md

@@ -0,0 +1,12 @@
+# Omada Health
+
+**Type:** Digital health company  
+**Focus:** Employer-sponsored chronic condition management programs  
+**Key Product:** Enhanced GLP-1 Care Track with behavioral wraparound
+
+## Overview
+Omada Health operates digital health programs for chronic condition management, primarily distributed through employer-sponsored benefits. Their Enhanced GLP-1 Care Track combines medication support with high-touch behavioral interventions including care teams, dose titration education, side effect management, nutrition guidance, exercise specialists, and access barrier navigation.
+
+## Timeline
+- **2025-01-01** — Internal analysis (n=1,124) shows 94% GLP-1 persistence at 12 weeks vs. 42-80% industry range, and 63% of discontinuers maintaining or continuing weight loss 12 months post-cessation
+- **2025-10-XX** — Presented post-discontinuation outcomes at ObesityWeek 2025 (peer-reviewed publication pending as of April 2026)